Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant unmet clinical need, and we are particularly focused on developing therapies in the regenerative medicine area. We are developing MultiStem®, a patented, a
dult-derived “off-the-shelf” stem cell product platform, for multiple disease indications in the areas of neurological, cardiovascular disease, inflammatory and immune disease, as well as other areas.We have currently six clinical stage programs – including a Phase 2 study in ischemic stroke, a Phase 2 clinical study for the treatment of damage from acute myocardial infarction, a exploratory clinical study in Acute Respiratory Distress Syndrome, and several others. We also have a portfolio of preclinical programs that we are advancing toward clinical stage development. Athersys has forged a network of strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research and clinical institutions, in the United States, Japan and Europe to further develop its platform and products.
